GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Haisco Pharmaceutical Group Co Ltd (SZSE:002653) » Definitions » Debt-to-Asset

Haisco Pharmaceutical Group Co (SZSE:002653) Debt-to-Asset : 0.30 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Haisco Pharmaceutical Group Co Debt-to-Asset?

Haisco Pharmaceutical Group Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1,089 Mil. Haisco Pharmaceutical Group Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥948 Mil. Haisco Pharmaceutical Group Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ¥6,843 Mil. Haisco Pharmaceutical Group Co's debt to asset for the quarter that ended in Mar. 2024 was 0.30.


Haisco Pharmaceutical Group Co Debt-to-Asset Historical Data

The historical data trend for Haisco Pharmaceutical Group Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haisco Pharmaceutical Group Co Debt-to-Asset Chart

Haisco Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.22 0.25 0.35 0.27

Haisco Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.29 0.26 0.27 0.30

Competitive Comparison of Haisco Pharmaceutical Group Co's Debt-to-Asset

For the Biotechnology subindustry, Haisco Pharmaceutical Group Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haisco Pharmaceutical Group Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Haisco Pharmaceutical Group Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Haisco Pharmaceutical Group Co's Debt-to-Asset falls into.



Haisco Pharmaceutical Group Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Haisco Pharmaceutical Group Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(940.975 + 865.529) / 6652.886
=0.27

Haisco Pharmaceutical Group Co's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1089.008 + 948.001) / 6842.783
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haisco Pharmaceutical Group Co  (SZSE:002653) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Haisco Pharmaceutical Group Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Haisco Pharmaceutical Group Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Haisco Pharmaceutical Group Co (SZSE:002653) Business Description

Traded in Other Exchanges
N/A
Address
No. 17, Sanxiang Avenue, Shannan District, Tibet Autonomous Region, Zetang, CHN, 856000
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
Executives
Fan Xiu Lian Directors, executives
Zheng Wei Directors, executives
Wang Meng Secretary Dong
Wang Jun Min Directors, executives
Deng Xiang Directors, executives
Liu Han Bing Supervisors
Zhang Xiao Xu Supervisors
Tan Hong Executives
Shen Ping Director
Liang Yong Supervisors
Chen Long Independent director
Duan Qing Liang Supervisors

Haisco Pharmaceutical Group Co (SZSE:002653) Headlines

No Headlines